(The Hill) – Pfizer and BioNTech are reported set to seek approval for booster shots of their COVID-19 vaccine for 16- and 17-year-olds. People familiar with the company’s plans told The Washington Post that the Food and Drug Administration (FDA) is expected to approve the company’s request surrounding the additional shots quickly.
Story continues below
- Tax: Turbo Tax opts out of IRS’s Free File program
- KRQE En Español: Lunes 17 de Enero 2022
- Crime: Suspect arrested after DNA links him to 1999 rape cold case
- New Mexico: Roundhouse Roundup: 2022 legislative session begins
Currently, Americans ages 18 and older are eligible for booster shots six months after their second dose of the Pfizer or Moderna vaccines, or two months after the single dose of the Johnson & Johnson vaccine.
The possible expansion of booster eligibility comes as concerns surrounding the new omicron variant mount.
“On Thursday, I’ll be putting forward a detailed strategy outlining how we’re going to fight COVID this winter, not with shutdowns or lockdowns but with more widespread vaccinations, boosters, testing and more,” Biden said.
Last week, in a statement about the variant, Biden touted booster shots and encouraged those who were eligible to get their additional doses.
“First, for those Americans who are fully vaccinated against severe COVID illness – fortunately, for the vast majority of our adults — the best way to strengthen your protection is to get a booster shot, as soon as you are eligible,” he said on Friday.
No omicron cases have yet been confirmed in the U.S., though experts believe they inevitably will be.
The Hill has reached out to Pfizer for comment.